JP2017516828A5 - - Google Patents

Download PDF

Info

Publication number
JP2017516828A5
JP2017516828A5 JP2016571118A JP2016571118A JP2017516828A5 JP 2017516828 A5 JP2017516828 A5 JP 2017516828A5 JP 2016571118 A JP2016571118 A JP 2016571118A JP 2016571118 A JP2016571118 A JP 2016571118A JP 2017516828 A5 JP2017516828 A5 JP 2017516828A5
Authority
JP
Japan
Prior art keywords
methyl
pharmaceutically acceptable
acceptable salt
dione
quinoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016571118A
Other languages
English (en)
Japanese (ja)
Other versions
JP6560257B2 (ja
JP2017516828A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2015/054173 external-priority patent/WO2015186062A1/en
Publication of JP2017516828A publication Critical patent/JP2017516828A/ja
Publication of JP2017516828A5 publication Critical patent/JP2017516828A5/ja
Application granted granted Critical
Publication of JP6560257B2 publication Critical patent/JP6560257B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016571118A 2014-06-03 2015-06-02 ピリミド[4,5−b]キノリン−4,5(3H,10H)−ジオン誘導体 Expired - Fee Related JP6560257B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14170974.1 2014-06-03
EP14170974 2014-06-03
PCT/IB2015/054173 WO2015186062A1 (en) 2014-06-03 2015-06-02 PYRIMIDO[4,5-b]QUINOLINE-4,5(3H,10H)-DIONE DERIVATIVES

Publications (3)

Publication Number Publication Date
JP2017516828A JP2017516828A (ja) 2017-06-22
JP2017516828A5 true JP2017516828A5 (enExample) 2018-06-28
JP6560257B2 JP6560257B2 (ja) 2019-08-14

Family

ID=50841688

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016571118A Expired - Fee Related JP6560257B2 (ja) 2014-06-03 2015-06-02 ピリミド[4,5−b]キノリン−4,5(3H,10H)−ジオン誘導体

Country Status (6)

Country Link
US (1) US9896448B2 (enExample)
EP (1) EP3152208B1 (enExample)
JP (1) JP6560257B2 (enExample)
CN (1) CN106459041B (enExample)
ES (1) ES2743184T3 (enExample)
WO (1) WO2015186062A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI688565B (zh) 2014-06-03 2020-03-21 瑞士商諾華公司 萘啶二酮(naphthyridinedione)衍生物
ES2743183T3 (es) 2014-06-03 2020-02-18 Novartis Ag Derivados de piridopirimidinodiona como supresores de mutaciones finalizadoras
WO2019225625A1 (ja) * 2018-05-23 2019-11-28 京都薬品工業株式会社 リードスルー誘導剤およびその医薬用途
WO2024194607A1 (en) * 2023-03-17 2024-09-26 Tay Therapeutics Limited Pyrimido[4,5-b][1,5]naphthyridine-4,5(3h,10h)-dione derivatives for the treatment of diseases associated with ptc mutations, such as e.g. cancer

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2884170B2 (ja) 1989-08-24 1999-04-19 株式会社フジモト・ブラザーズ 5−デアザフラビン系化合物を有効成分とする制癌剤
JP2989871B2 (ja) 1989-08-30 1999-12-13 大日本製薬株式会社 三環式化合物
JP2991382B2 (ja) * 1990-07-18 1999-12-20 大日本製薬株式会社 縮合三環式化合物およびその塩
WO1996028444A1 (en) 1995-03-15 1996-09-19 Pfizer Inc. 5,10-DIHYDROPYRIMIDO[4,5-b]QUINOLIN-4(1H)-ONE TYROSINE KINASE INHIBITORS
US6037345A (en) * 1998-01-13 2000-03-14 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to quinazolinedione and pyridopyrimidinedione derivatives
US6468990B1 (en) * 1999-05-17 2002-10-22 Queen's University At Kingston Method of inhibiting binding of nerve growth factor to p75 NTR receptor
WO2004006906A2 (en) 2002-07-15 2004-01-22 Combinatorx, Incorporated Methods for the treatment of neoplasms
BR0317183A (pt) * 2002-12-12 2005-11-01 Pharmacia Corp Método de usar compostos de aminocianopiridina como inibidores de proteìna quinase-2 ativada por proteìna quinase ativada por mitógeno
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
DK3549936T3 (da) 2003-04-11 2021-07-12 Ptc Therapeutics Inc 1,2,4-oxadiazol-benzoesyreforbindelse og dens anvendelse til nonsense-undertrykkelse og behandlingen af sygdom
EP3421481A1 (en) 2006-04-03 2019-01-02 Technion Research and Development Foundation Ltd. Novel aminoglycosides and uses thereof in the treatment of genetic disorders
EP2061470A4 (en) 2006-08-23 2010-10-06 Neurogen Corp HALOALKYL-SUBSTITUTED PYRIMIDINONE DERIVATIVES
WO2008084236A1 (en) * 2007-01-11 2008-07-17 Astrazeneca Ab Chemical compounds 635 : pyridopyrimidinediones as pde4 inhibitors
CA2709784A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
EP2422817A1 (en) 2010-07-29 2012-02-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Flavin-nucleic acid ligand conjugates
CN103189060A (zh) * 2010-08-05 2013-07-03 里尔法律与医疗卫生第二大学 用于对无义突变介导的疾病进行治疗的化合物和含有所述化合物的药物组合物
HK1209637A1 (en) 2012-12-13 2016-04-08 Novartis Ag Pyrimido [4,5-b]quinoline-4,5 (3h,10h)-diones as nonsense mutation suppressors
ES2743183T3 (es) 2014-06-03 2020-02-18 Novartis Ag Derivados de piridopirimidinodiona como supresores de mutaciones finalizadoras
TWI688565B (zh) 2014-06-03 2020-03-21 瑞士商諾華公司 萘啶二酮(naphthyridinedione)衍生物

Similar Documents

Publication Publication Date Title
JP2018021046A5 (enExample)
JP2016534063A5 (enExample)
JP2016040288A5 (enExample)
NZ723271A (en) Fused imidazole derivatives useful as ido inhibitors
EP4420679A3 (en) Lipids and lipid nanoparticle formulations for delivery of nucleic acids
JP2015537020A5 (enExample)
RU2018106453A (ru) Соединения
JP2019521988A5 (enExample)
JP2014502641A5 (enExample)
JP2016515628A5 (enExample)
RU2014135436A (ru) Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака
EA201492010A1 (ru) Применение высокой дозы лахинимода для лечения рассеянного склероза
RU2017134443A (ru) Способ лечения с применением традипитанта
JP2017516828A5 (enExample)
JP2016516773A5 (enExample)
JP2015512432A5 (enExample)
JP2015521617A5 (enExample)
JP2017513809A5 (enExample)
RU2013150861A (ru) Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний
JP2016529285A5 (enExample)
JP2015528501A5 (enExample)
JP2014515407A5 (enExample)
JP2017516829A5 (enExample)
JP2018522927A5 (enExample)
JP2020523317A5 (enExample)